In brief
The Trump administration has reached a deal with EMD Serono to lower the prices of key fertility medications, as part of new guidelines encouraging employers to provide separate fertility benefits. This step is seen as an initial move towards making in vitro fertilization (IVF) more affordable, though it falls short of previous promises to make IVF treatment free. Many families struggling with infertility hope that these measures will ease the financial burdens associated with fertility treatments.
WASHINGTON — The Trump administration has announced a significant reduction in the costs of common fertility medications through an agreement with drug manufacturer EMD Serono. This development, shared by President Trump, coincides with the introduction of new federal guidelines designed to encourage employers to offer fertility coverage separately from standard medical insurance plans, similar to dental and vision benefits.
This initiative provides early insight into the administration's commitment to making in vitro fertilization (IVF) more affordable for individuals seeking to expand their families, with preliminary steps taken following Trump's earlier executive order aimed at reducing IVF costs. However, it does not fulfill Trump's campaign promise to make IVF treatment completely free.
The fertility medication Gonal-f produced by EMD Serono is commonly used in IVF treatments, which often includes administering hormones to stimulate ovulation. Given the high costs associated with IVF cycles, which can reach several thousand dollars, this discount is seen as a stride toward alleviating financial pressures on prospective parents.
The newly discounted medications will be available through TrumpRx, a government platform that allows patients to purchase drugs directly from manufacturers. Additionally, the Food and Drug Administration (FDA) will work closely with EMD Serono to expedite the approval process for another fertility drug, Pergoveris, which is currently available in Europe.
Despite not meeting all promises for free IVF treatments, the announcement has been welcomed by fertility advocates. Roger Shedlin, CEO of WIN, a company specializing in fertility and family-building benefits, expressed optimism regarding the potential positive impact on overall IVF cycle costs. Families like that of Corinn O’Brien, who faced significant expenses during her IVF journey, share similar sentiments. Any reduction in drug costs is expected to make a meaningful difference in their attempts to conceive.
As the conversation around reproductive health continues to evolve, advocates emphasize the importance of employer coverage for fertility services, noting that for many, these are critical steps toward expanding their families.
